关于 浙江司太立制药股份有限公司 2023 年年度股东大会的 北京金诚同达律师事务所 法律意见书 金证法意【2024】字 0510 第 0227 号 中国北京市建国门外大街1号国贸大厦A座十层100004 电话：010-5706 8585 传真：010-8515 0267 北京金诚同达律师事务所 法律意见书 北京金诚同达律师事务所 关于 浙江司太立制药股份有限公司 2023 年年度股东大会的 法律意见书 金证法意【2024】字 0510 第 0227 号 致：浙江司太立制药股份有限公司 北京金诚同达律师事务所（以下简称"本所"）接受浙江司太立制药股份有 限公司（以下简称"公司"）的委托，指派本所郑寰律师、王迟律师（以下简称 "本所律师"）出席公司于2024年5月21日召开的2023年年度股东大会（以下简 称"本次股东大会"），对公司本次股东大会召开的合法性进行见证，并依法出 具本法律意见书。 本法律意见书系依据《中华人民共和国公司法》（以下简称"《公司法》"）、 《中华人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东大会 规则》（以下简称"《股东大会规则》"）、《上海证券交易所股票上市规则》 （以 ...

浙江司太立制药股份有限公司 2023 年年度股东大会 浙江司太立制药股份有限公司 2023 年年度股东大会 会议资料 股票代码：603520 会议时间：二〇二四年五月二十一日 | 2023 年年度股东大会会议须知 3 | | | | --- | --- | --- | | 2023 | | 年年度股东大会会议议程 4 | | 议案一 | | | | 公司 | 2023 | 年度董事会工作报告 6 | | 议案二 | | | | 公司 | 2023 | 年度监事会工作报告 11 | | 议案三 | | | | 公司 | | 2023 年度财务决算报告 15 | | 议案四 | | | | 公司 | | 2023 年年度报告（全文及摘要） 25 | | 议案五 | | | | 关于公司前次募集资金使用情况专项报告的议案 26 | | | | 议案六 | | | | 关于续聘公司 | | 2024 年度审计机构的议案 27 | | 议案七 | | | | 关于预计 2024 | | 年度对外担保的议案 30 | | 议案八 | | | | 关于公司申请银行综合授信的议案 33 | | | | 议案九 | | | | ...

证券代码：603520 证券简称：司太立 公告编号：2024-028 浙江司太立制药股份有限公司 关于召开 2023 年度暨 2024 年第一季度业绩暨现金 分红说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2024 年 05 月 09 日(星期四) 12:00 前将相关问题通过电子邮件 形式发送至本公司公开邮箱：stl@starrypharma.com。公司将在业绩说明会上就 投资者普遍关注的问题进行回答。 浙江司太立制药股份有限公司（以下简称"公司"）已于 2024 年 4 月 30 日发布公司 2023 年度报告及 2024 年第一季度报告，为便于广大投资者更全面深 入地了解公司 2023 年度及 2024 年第一季度经营成果、财务状况，公司计划于 2024 年 05 月 10 日下午 16:00-17:00 举行 2023 年度暨 2024 年第一季度业绩暨 现金分红说明会，就投资者关心的问题进行交流。 一、 说明会类型 本次投资者说明会以文字互动方式召开，公司将针对 202 ...

股票简称：司太立 股票代码：603520 浙江司太立制药股份有限公司 向特定对象发行股票 募集说明书 保荐机构（主承销商） 中国（上海）自由贸易试验区商城路 618 号 二〇二四年四月 （注册地址：浙江省台州市仙居县现代工业集聚区司太立大道 1 号） （注册稿） 声 明 本公司及全体董事、监事、高级管理人员承诺募集说明书及其他信息披露资 料不存在任何虚假记载、误导性陈述或重大遗漏，并对其真实性、准确性及完整 性承担相应的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责。投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引致的投资风险。 本募集说明书是本公司对本次向特定对象发行股票并上 ...

国泰君安证券股份有限公司 关于 浙江司太立制药股份有限公司 向特定对象发行股票 之 发行保荐书 保荐机构(主承销商) 国泰君安证券股份有限公司 GUOTAI JUNAN SECURITIES CO., LTD. (中国 (上海)自由贸易试验区商城路 618 号) 二〇二四年四月 国泰君安证券股份有限公司 关于浙江司太立制药股份有限公司 向特定对象发行股票之发行保荐书 国泰君安证券股份有限公司（以下简称"国泰君安"、"保荐机构"、"保 荐机构"）接受浙江司太立制药股份有限公司（以下简称"司太立"、"发行人"、 "公司"）的委托，担任司太立本次向特定对象发行 A 股股票（以下简称"本 次向特定对象发行"、"本次发行"）的保荐机构。 保荐机构及其保荐代表人根据《中华人民共和国公司法》、《中华人民共和 国证券法》、《上市公司证券发行注册管理办法》及《证券发行上市保荐业务管 理办法》等有关法律、法规和中国证券监督管理委员会（以下简称"中国证监会"） 的相关规定，诚实守信，勤勉尽责，严格按照依法制订的业务规则、行业执业规 范和道德准则出具本发行保荐书，并保证所出具文件的真实性、准确性和完整性。 3-1-1 | | | | ...

国泰君安证券股份有限公司 关于 浙江司太立制药股份有限公司 向特定对象发行股票 之 发行保荐书 保荐机构(主承销商) 国泰君安证券股份有限公司 GUOTAI JUNAN SECURITIES CO., LTD. (中国 (上海)自由贸易试验区商城路 618 号) 二〇二四年四月 国泰君安证券股份有限公司 关于浙江司太立制药股份有限公司 向特定对象发行股票之发行保荐书 国泰君安证券股份有限公司（以下简称"国泰君安"、"保荐机构"、"保 荐机构"）接受浙江司太立制药股份有限公司（以下简称"司太立"、"发行人"、 "公司"）的委托，担任司太立本次向特定对象发行 A 股股票（以下简称"本 次向特定对象发行"、"本次发行"）的保荐机构。 保荐机构及其保荐代表人根据《中华人民共和国公司法》、《中华人民共和 国证券法》、《上市公司证券发行注册管理办法》及《证券发行上市保荐业务管 理办法》等有关法律、法规和中国证券监督管理委员会（以下简称"中国证监会"） 的相关规定，诚实守信，勤勉尽责，严格按照依法制订的业务规则、行业执业规 范和道德准则出具本发行保荐书，并保证所出具文件的真实性、准确性和完整性。 3-1-1 | | | 3 ...

证券代码：603520 证券简称：司太立 公告编号：2024-027 浙江司太立制药股份有限公司 关于向特定对象发行股票会后事项 相关文件披露的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 浙江司太立制药股份有限公司（以下简称公司）2023 年向特定对象发行股 票已于 2023 年 10 月 19 日收到上海证券交易所（以下简称上交所）出具的《关 于浙江司太立制药股份有限公司向特定对象发行股票审核意见的通知》，具体内 容详见公司在上交所网站（www.sse.com.cn）披露的《浙江司太立制药股份有限 公司关于向特定对象发行股票申请获上海证券交易所审核通过的公告》（公告编 号：2023-074）；于 2024 年 3 月 13 日获得中国证券监督管理委员会（以下简称 中国证监会）出具的《关于浙江司太立制药股份有限公司向特定对象发行股票注 册的批复》（证监许可[2024]373 号），具体内容详见公司在上交所网站 （www.sse.com.cn）披露的《浙江司太立制药股份有限公司关于向特定对象发行 股票申请获得中国 ...

Financial Performance - The company's operating revenue for 2023 was approximately CNY 2.20 billion, representing a 3.04% increase compared to CNY 2.13 billion in 2022[23]. - The net profit attributable to shareholders for 2023 was CNY 44.23 million, a significant recovery from a loss of CNY 75.85 million in 2022, marking a 158.32% increase[23]. - The net cash flow from operating activities for 2023 was CNY 44.55 million, improving by 156.85% from a negative cash flow of CNY 78.37 million in the previous year[23]. - Total assets at the end of 2023 amounted to CNY 5.52 billion, reflecting a 4.04% increase from CNY 5.30 billion at the end of 2022[23]. - The net assets attributable to shareholders decreased slightly by 0.72% to CNY 1.75 billion at the end of 2023, compared to CNY 1.77 billion at the end of 2022[23]. - The basic earnings per share rose to 0.13 yuan, marking a 159.09% increase from a loss of 0.22 yuan in 2022[24]. - The weighted average return on equity improved to 2.53%, an increase of 6.34 percentage points from -3.81% in 2022[24]. - The net profit after deducting non-recurring gains and losses was 35.7144 million yuan, up 136.47% year-on-year[33]. - The company reported a significant reduction in credit impairment losses for the year, contributing to improved profitability[24]. - The absence of goodwill impairment in 2023, which was 114.7478 million yuan in 2022, positively impacted the net profit turnaround[34]. Business Operations and Strategy - The company successfully registered new products, including iodine mepivacaine injection and iodine benzyl alcohol injection, enhancing its product portfolio[33]. - The company continues to optimize its product layout and accelerate consistency evaluations to enhance market competitiveness[33]. - The company is actively participating in market competition and pursuing strategic development plans despite ongoing external pressures[33]. - The company's revenue increased by 3.04% during the reporting period, driven by the growth in the formulation business and improved management of accounts receivable, resulting in a reduction of credit impairment losses by 9.64 million yuan compared to the previous year[35]. - The CMO/CDMO business achieved sales revenue of 97.25 million yuan, representing a year-on-year growth of 87.54%[36]. - Domestic formulation sales reached 490 million yuan, with a year-on-year increase of 42.44%, supported by successful bids in national and provincial procurement[36]. - The company is advancing its "intermediate-active pharmaceutical ingredient-formulation" integrated industrial layout, with several projects completing acceptance and entering trial production[36]. - The company has established a specialized academic team to promote its products in the imaging field, enhancing its sales network across various provinces[36]. - The company is focusing on cost reduction and efficiency improvement through technology upgrades and digital transformation, aiming for higher operational efficiency[35]. - The company successfully won bids for the continuation of Iopamidol procurement in multiple provinces, which is expected to provide new growth points for formulation sales[37]. Research and Development - The company has invested in R&D, with over 30 authorized invention patents and collaborations with several prestigious universities and research institutions[54]. - The company has established multiple R&D bases across various locations, including Zhejiang and Shanghai, to enhance its research capabilities[96]. - The company’s R&D projects are managed under strict protocols, with regular assessments and evaluations conducted bi-weekly[97]. - The company is focusing on expanding its product offerings in the imaging agent market, with multiple products under development and approval processes[99]. - The company has a strategic focus on ensuring that its research and development expenditures are aligned with its long-term growth objectives[102]. Market and Regulatory Environment - The global pharmaceutical market is projected to reach $1.9 trillion by 2027, indicating a strong growth trajectory for the industry[38]. - The pharmaceutical manufacturing industry in China saw a decline in revenue by 3.70% and a profit drop of 15.1% in 2023, indicating a challenging market environment[50]. - The National Medical Insurance Bureau has initiated the regularization of the adjustment of the national medical insurance drug list, which may impact the company's product pricing and market access[45]. - The company faces heightened compliance requirements due to new anti-corruption policies in the healthcare sector, which aim to ensure sustainable and healthy development[89]. - The company recognizes the high investment and risk associated with drug R&D, which may impact profitability if products miss market opportunities[116]. Governance and Management - The company has appointed new independent directors and supervisors, enhancing its governance structure[126]. - The management team has a diverse background with significant experience in various sectors, which is expected to drive future growth[126]. - The company has a structured compensation management system in place, aligning remuneration with performance assessments[132]. - The company has maintained a consistent leadership team with several members serving in their roles for over five years[130]. - The company has a clear policy regarding the avoidance of conflicts of interest during remuneration discussions[132]. Environmental and Social Responsibility - The company invested 12,933.12 million yuan in environmental protection during the reporting period[164]. - The company achieved a total wastewater discharge of 565,693 tons in 2023, with specific emissions of COD at 178.159 tons and ammonia nitrogen at 4.874 tons[165]. - The company has established an internal control system and will disclose its self-evaluation report by April 30, 2024[161]. - The company has implemented a comprehensive environmental risk emergency response plan, ensuring effective management of potential environmental incidents[179]. - The total investment in charitable donations amounted to 1.05 million yuan, all of which was allocated to charitable contributions[186]. Future Outlook - The company provided guidance for the next fiscal year, projecting a revenue growth of 25% and aiming for 1.875 billion in total revenue[129]. - The company plans to enhance brand building and aims to establish a trusted brand image in the contrast agent sector, leveraging national procurement policies[111]. - The company aims to accelerate its CMO/CDMO business layout in 2024, focusing on building an independent CDMO technology platform and enhancing quality control capabilities[112]. - The company is exploring potential acquisitions to enhance its product portfolio, with a budget of 100 million allocated for this purpose[129].

Financial Performance - The company's operating revenue for Q1 2024 was CNY 642,300,553.98, representing a year-on-year increase of 13.50%[5] - The net profit attributable to shareholders for the same period was CNY 12,282,528.03, reflecting a growth of 28.37% compared to the previous year[5] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 9,830,979.61, which is an increase of 31.85% year-on-year[5] - The basic and diluted earnings per share were both CNY 0.04, up by 33.33% year-on-year[5] - Total operating revenue for Q1 2024 reached ¥642.30 million, a 13.5% increase from ¥565.91 million in Q1 2023[19] - Net profit for Q1 2024 was ¥12.56 million, representing a 34.5% increase compared to ¥9.33 million in Q1 2023[20] - Earnings per share for Q1 2024 were ¥0.04, up from ¥0.03 in Q1 2023[21] Cash Flow and Liquidity - The net cash flow from operating activities reached CNY 92,090,350.43, showing a significant increase of 318.83% compared to the same period last year[5] - Cash flow from operating activities in Q1 2024 was ¥448.76 million, a decrease from ¥487.45 million in Q1 2023[24] - The net cash flow from operating activities for Q1 2024 was $92,090,350.43, a significant improvement compared to a net outflow of $42,083,050.09 in Q1 2023[25] - Total cash inflow from financing activities was $548,150,000.00, while cash outflow was $533,518,408.58, resulting in a net cash flow of $14,631,591.42 for Q1 2024[26] - The company reported a total cash and cash equivalents balance of $462,366,100.72 at the end of Q1 2024, down from $672,800,197.89 at the end of Q1 2023[26] - Cash outflow for purchasing goods and services was $349,390,319.25 in Q1 2024, compared to $460,940,904.99 in Q1 2023, indicating a reduction in operational expenses[25] - The cash paid for debt repayment was $209,725,837.76 in Q1 2024, significantly lower than $515,880,317.54 in Q1 2023[26] Assets and Liabilities - Total assets at the end of Q1 2024 were CNY 5,351,668,879.89, a decrease of 2.99% from the end of the previous year[6] - The company's current liabilities totaled ¥2,695,139,766.22, down from ¥2,931,391,132.52, indicating a reduction of about 8.0%[16] - Accounts receivable increased to ¥440,537,040.40 from ¥342,223,599.03, representing a growth of approximately 28.7%[15] - Inventory decreased to ¥960,125,774.51 from ¥1,148,278,539.64, showing a decline of around 16.5%[15] - The company's total liabilities were reported at ¥3,580,475,836.87, down from ¥3,757,520,423.56, reflecting a decrease of approximately 4.7%[16] - The company's cash and cash equivalents stood at ¥522,964,070.88, down from ¥565,134,168.92, a decrease of about 7.4%[14] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 32,595[11] - The company's equity attributable to shareholders increased to CNY 1,764,619,173.92, marking a rise of 0.69% from the previous year-end[6] - The total equity attributable to shareholders reached ¥1.76 billion, an increase from ¥1.75 billion in the previous quarter[17] - The total liabilities and equity amounted to ¥5.35 billion, down from ¥5.52 billion in the previous quarter[17] Expenses and Investments - The company reported a significant increase in sales expenses by 34.90%, attributed to enhanced promotion of its formulation business[8] - Research and development expenses for Q1 2024 totaled ¥32.12 million, a decrease of 7.8% from ¥34.84 million in Q1 2023[20] - Financial expenses increased to ¥30.82 million in Q1 2024, compared to ¥20.18 million in Q1 2023[20] - Investment activities resulted in a net cash outflow of $96,581,468.55 in Q1 2024, compared to a net outflow of $72,276,230.01 in Q1 2023[25] Government Support - The company received government subsidies amounting to CNY 3,526,824.49, contributing positively to the net profit[7] Future Outlook - The company plans to continue focusing on cost management and operational efficiency to improve cash flow in future quarters[25]

证券代码：603520 证券简称：司太立 公告编号：2024-014 浙江司太立制药股份有限公司 2024 年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (一) 股东大会召开的时间：2024 年 4 月 10 日 (二) 股东大会召开的地点：浙江省仙居县现代工业集聚区丰溪西路 9 号公司 行政楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 18 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 131,305,051 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股 | | | 份总数的比例（%） | 38.3356 | (二) 涉及重大事项，5%以下股东的表决情况 | 议案 | 议案名称 | 同意 | | 反对 | | 弃权 | | | --- | --- | --- | --- | --- | --- ...